CanBas Co., Ltd.
JPX: 4575.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Takumi Kawabe
- Employees
- 11
- Headquarters
- Numazu, Japan
- IPO year
- 2009
- Market cap
- ¥13.5B
- Website
- https://www.canbas.co.jp
Loading 4575…
Loading profile data…Frequently asked questions about 4575
What does CanBas Co., Ltd. (4575.T) do?
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stem...
Where does 4575.T trade?
CanBas Co., Ltd. (4575.T) trades on the Tokyo Stock Exchange.
What sector is 4575.T in?
CanBas Co., Ltd. (4575.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CanBas Co., Ltd.?
Takumi Kawabe is the chief executive officer of CanBas Co., Ltd. (4575.T).
Where is CanBas Co., Ltd. headquartered?
CanBas Co., Ltd. is headquartered in Japan.
Does 4575.T pay a dividend?
CanBas Co., Ltd. (4575.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4575.T go public?
CanBas Co., Ltd. (4575.T) completed its initial public offering in 2009.